Challenges and Breakthroughs of DC Vaccines in Tumor Immunotherapy
Currently,one of the most promising tools in tumor immunotherapy is dendritic cell(DC)vaccines.DC vaccines are based on the uptake of antigens delivered by DCs and the activation of T cells to induce anti-tumor effects.However,traditional DC vaccines have made slow progress in the treatment of solid tumors due to the limited activity of monocyte-derived DCs and tumor-mediated immunosuppression.Novel DC vaccines and DC vaccine combination therapies offer new ways to improve tumor treatment compared to traditional DC vaccine therapy.This article reviews the major challenges faced by traditional DC vaccines in the field of solid tumor therapy,the current research progress of novel DC vaccines,and DC vaccine combination therapy strategies.It also discusses their development prospects and provides new ideas for future research and product development of DC vaccines in tumor therapy.
DC vaccinesCancer vaccineCombination therapyImmunosuppression
NETL
NSTL
万方数据
